Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.

Lin JS, Webber EM, Senger CA, Holmes RS, Whitlock EP.

Am J Cancer Res. 2011 May 15;1(5):650-62.

2.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
3.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
4.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
5.

Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.

Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL.

Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13. Review. Erratum in: Int J Cancer. 2014 Jul 15;135(2):E2.

7.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

8.

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.

Mao C, Yang ZY, Hu XF, Chen Q, Tang JL.

Ann Oncol. 2012 Jun;23(6):1518-25. doi: 10.1093/annonc/mdr464. Epub 2011 Oct 29. Review.

PMID:
22039088
9.

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.

Westwood M, van Asselt T, Ramaekers B, Whiting P, Joore M, Armstrong N, Noake C, Ross J, Severens J, Kleijnen J.

Health Technol Assess. 2014 Oct;18(62):1-132. doi: 10.3310/hta18620. Review.

10.

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.

Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.

Ann Oncol. 2015 Jan;26(1):13-21. doi: 10.1093/annonc/mdu378. Epub 2014 Aug 12. Review.

PMID:
25115304
11.

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

van Brummelen EMJ, de Boer A, Beijnen JH, Schellens JHM.

Oncologist. 2017 Jul;22(7):864-872. doi: 10.1634/theoncologist.2017-0031. Epub 2017 Jun 2. Review.

PMID:
28576857
12.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
13.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2. Review.

PMID:
19188670
14.

[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].

Fabian P, Berkovcov√° J.

Cesk Patol. 2011 Oct;47(4):154-8. Review. Czech.

PMID:
22145213
15.

[Predictive biomarkers for anti-EGFR antibodies].

Bando H, Yoshino T.

Gan To Kagaku Ryoho. 2012 Nov;39(11):1618-25. Review. Japanese.

PMID:
23152013
16.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F, Barni S.

Eur J Cancer. 2015 Mar;51(5):587-94. doi: 10.1016/j.ejca.2015.01.054. Epub 2015 Feb 9. Review.

PMID:
25673558
17.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
18.

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.

Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ.

Br J Cancer. 2015 Jun 9;112(12):1888-94. doi: 10.1038/bjc.2015.173. Epub 2015 May 19. Review.

19.

Personalized treatment for advanced colorectal cancer: KRAS and beyond.

Patel GS, Karapetis CS.

Cancer Manag Res. 2013 Nov 21;5:387-400. doi: 10.2147/CMAR.S35025. eCollection 2013. Review.

20.

Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.

Zhai Z, Yu X, Yang B, Zhang Y, Zhang L, Li X, Sun H.

Semin Cell Dev Biol. 2017 Apr;64:107-115. doi: 10.1016/j.semcdb.2016.08.033. Epub 2016 Aug 27. Review.

PMID:
27578007

Supplemental Content

Support Center